The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
REGULATORY
Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
A key health ministry advisory committee on September 4 gave its thumbs up to Rakuten Medical’s sakigake-designated antibody drug conjugate (ADC) (cetuximab sarotalocan sodium), based on its photoimmunotherapy technology platform, placing the drug in line for approval in September, along…
To read the full story
REGULATORY
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
- MHLW Seeks Nearly 33 Trillion Yen in Unusual Budget Request for FY2021; COVID-19 Quota Yet to Come
September 29, 2020
- MHLW’s Health Policy Bureau Requests New Budgets to Forge Clinical Trial Network in Asia
September 29, 2020
- Coronavirus Panel OKs Interim Report on COVID-19 Vaccination, Sorts Out Roles of Central, Local Govts
September 29, 2020
- MHLW Economic Affairs Chief Not Optimistic about Reaching 80% Generic Target
September 28, 2020
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Despite the worldwide focus on inclusivity and diversity, it will take immediate action to counteract Japan’s growing gender gap. Study after study has proven that companies with more women in senior roles perform better financially, gaining a competitive edge from…